CYP2B6 and myotonic dystrophy type 2: The studies including DM2 patients revealed that the therapy induces plasma membrane reparation and increases the surface density in ER membranes of hepatocytes together with an elimination of liver fat, a decrease both in blood glucose and plasma IRI levels and enhancement of P450-mediated AP clearance [7].